DDX52 Inhibitors

The chemical class known as DDX52 inhibitors comprises a set of compounds strategically designed to modulate cellular processes associated with DDX52. Actinomycin D, a transcription inhibitor, interferes with RNA synthesis, impacting processes associated with DDX52. Similarly, Actinomycin V, another transcription inhibitor, may influence DDX52 through its effects on RNA synthesis. Ellipticine, an intercalating agent impacting DNA structure, may have a indirect impact on DDX52 by influencing DNA-related processes. Camptothecin and Mitoxantrone, topoisomerase inhibitors, alter DNA topology, influencing processes associated with DDX52. Anthracycline antibiotics, such as Daunorubicin and Doxorubicin, impact DNA structure, with indirect effects on DDX52 through DNA-related processes.

Moreover, Trichostatin A, an HDAC inhibitor, impacts chromatin structure, indirectly influencing DDX52 through its effects on DNA-related processes. NSC 663284, a DNA-binding small molecule, modulates DNA structure, affecting processes linked to DDX52. Amsacrine, a topoisomerase II inhibitor, alters DNA topology, influencing processes associated with DDX52. In addition, the antimetabolite 5-Fluorouracil disrupts DNA synthesis, affecting pathways linked to DDX52 modulation. 6-Mercaptopurine, a purine analog, impacts nucleotide synthesis, influencing pathways associated with DDX52 modulation. Together, these inhibitors provide a diverse toolkit for investigating the intricate cellular processes associated with DDX52, offering valuable insights for future research in this field.